The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas / A.J. Ferreri, S. Dell'Oro, M. Foppoli, M. Bernardi, A.A. Brandes, A. Tosoni, M. Montanari, M. Balzarotti, M. Spina, F. Ilariucci, F. Zaja, C. Stelitano, F. Bobbio, G. Corazzelli, L. Baldini, M. Ponzoni, P. Picozzi, F. Caligaris Cappio, M. Reni. - In: NEUROLOGY. - ISSN 0028-3878. - 66:9(2006), pp. 1435-1438.
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas
L. Baldini;
2006
Abstract
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
